CCRM
Aileen Gracias is a seasoned professional with extensive experience in technology and venture development within the biotechnology and healthcare sectors. Currently serving as a Senior Associate at CCRM since October 2018, Aileen has held multiple roles, including Manager and Senior Lead. Previous positions include Analyst Intern at Shift Health and Consultant with the University Consulting Group, alongside significant contributions as a Postdoctoral Fellow at the University of Toronto and involvement in international regenerative medicine programs. Aileen's expertise extends to research and project coordination in clinical-stage biotech firms, as well as leadership in mentorship initiatives connecting students with life science professionals. Aileen holds a PhD in Neuroscience from Karolinska Institutet and an Honors Bachelor of Science in Biochemistry and Biomedical Toxicology from the University of Toronto.
This person is not in any teams
This person is not in any offices
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.